Trial Profile
The Effect of the Addition of Dronedarone to, Versus Increase of, Existing Conventional Rate Control Medication on Ventricular Rate During Paroxysmal or Persistent Atrial Fibrillation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2012
Price :
$35
*
At a glance
- Drugs Dronedarone (Primary) ; Beta-adrenergic receptor antagonists; Calcium channel antagonists; Digoxin
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Acronyms AFRODITE
- Sponsors Sanofi
- 09 Nov 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
- 09 Nov 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
- 09 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.